Disease · MONDO_0011479
postural orthostatic tachycardia syndrome due to NET deficiency
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. postural orthostatic tachycardia syndrome due to NET deficiency. Diseases, record MONDO_0011479. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0011479
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- familial orthostatic tachycardia due to norepinephrine transporter deficiency, orthostatic intolerance, orthostatic intolerance due to NET deficiency
- Open Targets
Drugs9
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| IVABRADINE | CHEMBL471737 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ALBUMIN HUMAN | CHEMBL1201451 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SODIUM CHLORIDE | CHEMBL1200574 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EFGARTIGIMOD ALFA | CHEMBL4297551 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GANIRELIX ACETATE | CHEMBL5314377 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IRON SUCROSE | CHEMBL1200823 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METOPROLOL | CHEMBL13 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PROGESTERONE | CHEMBL103 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ATOMOXETINE | CHEMBL641 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets6
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRB1 | Beta-1 adrenergic receptor | 1 | Beta-1 adrenergic receptor antagonist | Phase 2 | https://conductscience.org/library/genes/153 | Drugs and targets |
| FCGRT | IgG receptor FcRn large subunit p51 | 1 | IgG receptor FcRn large subunit p51 antagonist | Phase 2 | https://conductscience.org/library/genes/2217 | Drugs and targets |
| GNRHR | Gonadotropin-releasing hormone receptor | 1 | Gonadotropin-releasing hormone receptor antagonist | Phase 2 | https://conductscience.org/library/genes/2798 | Drugs and targets |
| HCN4 | Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 | 1 | Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker | Phase 3 | https://conductscience.org/library/genes/10021 | Drugs and targets |
| PGR | Progesterone receptor | 1 | Progesterone receptor agonist | Phase 2 | https://conductscience.org/library/genes/5241 | Drugs and targets |
| SLC6A2 | Sodium-dependent noradrenaline transporter | 1 | Norepinephrine transporter inhibitor | Phase 1 | https://conductscience.org/library/genes/6530 | Drugs and targets |
Trials7
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01153581 | Sex Hormones and Orthostatic Tolerance | Phase 2 | 109 | 2017-01-30 | Orthostatic Intolerance | GANIRELIX ACETATE, PROGESTERONE | Its record names the disease | ClinicalTrials.gov |
| NCT05633407 | Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS | Phase 2 | 53 | 2025-05-23 | Postural Orthostatic Tachycardia Syndrome | EFGARTIGIMOD ALFA | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03182725 | Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome | Phase 3 | 37 | 2021-06-29 | Postural Orthostatic Tachycardia Syndrome | IVABRADINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03808740 | Orthostatic Intolerance After Bariatric Surgery | Phase 1 | 10 | 2024-09-27 | Orthostatic Intolerance | ATOMOXETINE | Its record names the disease | ClinicalTrials.gov |
| NCT00865917 | Cardiovascular Effects of Selective I(f)-Channel Blockade | Phase 2 | 40 | Postural Orthostatic Tachycardia Syndrome | IVABRADINE, METOPROLOL | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03365414 | A Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe POTS | Phase 3 | 0 | Postural Orthostatic Tachycardia Syndrome | ALBUMIN HUMAN, SODIUM CHLORIDE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT04855266 | Iron Sucrose in Patients With Iron Deficiency and POTS | Phase 2 | 0 | Iron-deficiency, Postural Orthostatic Tachycardia Syndrome | IRON SUCROSE | Open Targets' reading of its record | ClinicalTrials.gov |
Comparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ivabradine vs Placebo: deaths from any cause | 0 of 37 | 0 of 37 | 74 | NCT03182725 | Trial comparisons |
| Ivabradine vs Placebo: serious adverse events | 0 of 37 | 0 of 37 | 74 | NCT03182725 | Trial comparisons |
| Efgartigimod vs Placebo: deaths from any cause | 0 of 36 | 0 of 17 | 53 | NCT05633407 | Trial comparisons |
| Efgartigimod vs Placebo: Number of Participants With ADAs Against Efgartigimod | 5 of 36 | 1 of 17 | 53 | NCT05633407 | Trial comparisons |
| Efgartigimod vs Placebo: serious adverse events | 0 of 36 | 0 of 17 | 53 | NCT05633407 | Trial comparisons |
Papers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0011479
GET https://conductscience.org/api/diseases/v1/MONDO_0011479/drugs